Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 8/20 | 0.50 |
| ▸ | GRB2 | P62993 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | BAD | Q92934 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.41 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16595068 | 0.94 | BCL2L1 (0.52) | KCNN4GRB2CES2CES1BCL2L1 | |
| SCHEMBL13199203 | 0.90 | GRB2 (0.57) | GRB2CES2CES1RAB9ANPC1 | |
| SCHEMBL23588301 | 0.83 | CES2 (0.56) | GRB2CES2CES1RAB9ANPC1 | |
| SCHEMBL13199251 | 0.83 | GRB2 (0.52) | GRB2CES2CES1BCL2L1BAD | |
| SCHEMBL28759803 | 0.81 | ESR1 (0.50) | GRB2MAPTHTTCYP1A1CYP1B1 | |
| SCHEMBL4028655 | 0.81 | KCNN4 (0.50) | KCNN4CES2CES1BCL2L1BAD | |
| SCHEMBL354556 | 0.80 | CYP1A2 (0.52) | KCNN4GRB2CES2CES1RAB9A | |
| SCHEMBL164346 | 0.79 | KCNN4 (0.48) | KCNN4CES2CES1RAB9ANPC1 | |
| SCHEMBL11091284 | 0.79 | KCNN4 (0.65) | KCNN4CES2CES1RAB9ANPC1 | |
| SCHEMBL4312243 | 0.79 | MIF (0.50) | GRB2CES2CES1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12474342-B2 | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies | CELGENE CORPORATION (US) | 2025-11-18 | — | — | US | disclosed |
| CN-118909031-B | Anti-coronavirus compounds, compositions and uses thereof | 上海柯君医药科技有限公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-118909031-A | Anti-coronavirus compounds, compositions and uses thereof | 上海柯君医药科技有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118488949-A | Anti-coronavirus compounds, compositions and uses thereof | 上海柯君医药科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118390080-A | Method for preparing fluorine-containing aromatic hydrocarbon carboxylic acid by electrocatalytic fixation of carbon dioxide | 上海第二工业大学 | 2024-07-26 | — | — | CN | disclosed |
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3808346-B1 | ANTIPROLIFERATIVE COMPOUNDS FOR USE IN THE TREATMENT OF LEUKEMIA | CELGENE CORP (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023125825-A1 | ANTICORONVIRAL COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| WO-2010002472-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20090124600-A1 | N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| EP-1874318-A2 | N-ALKYL-AZACYCLOALKYL NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113471-A2 | N-ALKYL-AZACYCLOALKYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| EP-0117100-B1 | TRIAZOLE ANTIFUNGAL AGENTS | Pfizer Limited (GB) | 1986-12-10 | — | — | EP | disclosed |
| US-4616026-A | Antifungal 2-aryl-1,1-difluoro-3-(1H-1,2,4-triazol-1-yl)2-propanols | PFIZER INC. (US) | 1986-10-07 | — | — | US | disclosed |
| EP-0117100-A1 | Triazole antifungal agents | Pfizer Limited (GB) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12474342-B2 | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies | TSG101, BRCA1, TP53 | KCNN4 4762/4885GRB2 1560/4885CES2 1394/4885 |
| US-20090124600-A1 | N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists | GRIN2B, GRIN2A, GRIN1 | KCNN4 440/4885GRB2 1283/4885CES2 3659/4885 |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | KCNN4 2348/4885GRB2 697/4885CES2 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.